Bayer’s Eylea™ 8 mg Recommended for EU Approval with Extended 6-Month Treatment Interval for Major Retinal Diseases Bayer has today announced a significant milestone in the treatment of retinal diseases,…
GSK’s Blenrep Combinations Receive Positive CHMP Opinion for Relapsed or Refractory Multiple Myeloma, Signaling Expanded Access Across Europe In a significant step forward for the treatment of multiple myeloma, GSK…
NICE Recommends FILSPARI® (sparsentan) for Routine Use in the NHS to Treat Adults with IgA Nephropathy, Marking a Significant Step Forward in Rare Kidney Disease Management CSL Vifor has announced…
Rethinking Nicotine: CVS Health Survey Uncovers Widespread Misconceptions About E-Cigarette Safety Among Young Adults Over the past few decades, the public conversation around tobacco and nicotine use has transformed dramatically.…
Trodelvy Marks Breakthrough in First-Line mTNBC Treatment with Positive Phase 3 ASCENT-03 Results Gilead Sciences has announced encouraging topline results from its Phase 3 ASCENT-03 clinical trial evaluating Trodelvy® (sacituzumab…
Bayer Launches Centafore Imaging Core Lab to Revolutionize Clinical Trial Imaging and SaMD Development Bayer, a global leader in healthcare and life sciences, today officially announced the launch of its…
Merck Highlights Breakthrough Innovations in Advanced Cancers and Rare Tumors at ASCO 2025 Merck, a global leader in science and technology, has once again showcased its commitment to transforming cancer…
GSK’s Nucala (Mepolizumab) Receives US FDA Approval as Add-On Maintenance Treatment for Adults with Eosinophilic Phenotype COPD GSK has officially announced a significant milestone in the treatment of chronic obstructive…
Dr. Mark Stetter Elected to Zoetis Board of Directors, Bringing Decades of Veterinary Leadership and Animal Health Expertise Zoetis,a global leader in animal health, announced a significant addition to its…
Regeneron’s Linvoseltamab Combinations Show Strong Early Signals in Relapsed/Refractory Multiple Myeloma in Phase 1b Trial Regeneron Pharmaceuticals,has reported encouraging early findings from the ongoing Phase 1b LINKER-MM2 study, evaluating linvoseltamab…
Bristol Myers Squibb Showcases Expansive Oncology Portfolio and Groundbreaking Clinical Research at ASCO 2025 Annual Meeting Bristol Myers Squibb is set to make a significant impact at the 2025 American…
XTANDI Delivers Sustained Five-Year Survival Benefit in Metastatic Hormone-Sensitive Prostate Cancer: Landmark Findings from ARCHES and ENZAMET Trials Presented at ASCO 2025 Astellas Pharma Inc. and Pfizer Inc. have announced…